Capital Fund Management S.A. Revance Therapeutics, Inc. Transaction History

Capital Fund Management S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $84,556 - $184,816	7,372 Added 25.25%	36,572 $419,000
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $721,240 - $1.1 Million	29,200 New	29,200 $739,000
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $309,608 - $518,154	16,900 New	16,900 $311,000
Q4 2020 Feb 12, 2021	SELL	$23.41 - $28.34 $326,405 - $395,144	-13,943 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $323,895 - $478,244	13,943 New	13,943 $350,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.